glp-1 and eating disorder Treating Clients Amid the Craze: A Complex Landscape #504: Adult Eating Disorders in
Description
doi:10.3389/fpubh.2022.996179 8
How to individualize renoprotective therapy in obese patients with chronic kidney disease: A commentary by the Diabesity Working Group of the ERA
First description in humans of the ability of SGLT2 inhibitors to attenuate glomerular hyperfiltration, likely by affecting tubuloglomerular feedback mechanisms
GLP-1-stimulation of energy expenditure
Nunes, K
A hundred percent of the time had some of, some form of culture food
